Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...

With (almost) no fees and unlimited refunds for ATM charges, Novo business checking is a good option for small-business owners on the go. But Novo’s customer support is lacking, and you can’t ...

A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

TransCon CNP matches BioMarin's Voxzogo for achondroplasia with plans for regulatory filings in 2025, showing potential for ...

J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

Studied over 36 weeks, in doses from 1.25 mg to 20 mg, patients taking amycretin experienced only "mild to moderate" gastrointestinal side effects, says Novo, and in exchange enjoyed a 9.7% average ...